CLINICAL TRIALS PROFILE FOR AMERGE
✉ Email this page to a colleague
All Clinical Trials for AMERGE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00487578 ↗ | Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction | Terminated | Clinvest | Phase 4 | 2006-10-01 | The purpose of this study is to determine whether naratriptan, a medication approved for treatment of migraine, is effective in the treatment of post traumatic headache associated with cognitive dysfunction. |
| NCT00487578 ↗ | Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction | Terminated | GlaxoSmithKline | Phase 4 | 2006-10-01 | The purpose of this study is to determine whether naratriptan, a medication approved for treatment of migraine, is effective in the treatment of post traumatic headache associated with cognitive dysfunction. |
| NCT00487578 ↗ | Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction | Terminated | Cady, Roger, M.D. | Phase 4 | 2006-10-01 | The purpose of this study is to determine whether naratriptan, a medication approved for treatment of migraine, is effective in the treatment of post traumatic headache associated with cognitive dysfunction. |
| NCT01332383 ↗ | Special Drug Use Investigation for AMERGE® Tablet (Long-term) | Completed | GlaxoSmithKline | 2009-05-01 | To investigate the long-term safety and efficacy of AMERGE (naratriptan hydrochloride) on Japanese patients with migraine headache in clinical setting | |
| NCT01376193 ↗ | Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet | Completed | GlaxoSmithKline | 2009-04-01 | The study is designed to investigate the information on safety and efficacy of naratriptan tablets on Japanese subjects with migraine headache during Japanese post-marketing surveillance period. | |
| NCT03066544 ↗ | Status Migrainosus - Differentiating Between Responders and Non-responders | Unknown status | Hartford HealthCare | Phase 1/Phase 2 | 2016-11-30 | The main goal of this study is to determine whether it is possible - in the setup of routine clinical care - to identify in individual patients who are clear responders to drug X, common denominators that are absent in individual patients who are non-responders to the same drug, and vice versa. All currently available knowledge about migraine pathophysiology will be utilized, using as much time as is needed to ask as many questions as are necessary, in an attempt to profile clear responders and clear non-responders. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for AMERGE
Condition Name
Clinical Trial Locations for AMERGE
Trials by Country
Clinical Trial Progress for AMERGE
Clinical Trial Phase
Clinical Trial Sponsors for AMERGE
Sponsor Name
